Satellite 2 repeat DNA in blood plasma as a candidate biomarker for the detection of cancer.

Autor: Özgür E; Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey., Mayer Z; Institute of Laboratory Medicine, German Heart Center, Munich Technical University, Munich, Germany., Keskin M; Department of Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey., Yörüker EE; Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey., Holdenrieder S; Institute of Laboratory Medicine, German Heart Center, Munich Technical University, Munich, Germany., Gezer U; Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. Electronic address: ugurd@istanbul.edu.tr.
Jazyk: angličtina
Zdroj: Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2021 Mar; Vol. 514, pp. 74-79. Date of Electronic Publication: 2020 Dec 31.
DOI: 10.1016/j.cca.2020.12.008
Abstrakt: Background and Aim: Currently, cancer biomarkers are associated with low diagnostic performance, and the notion of using cell-free DNA (cfDNA) as a surrogate cancer biomarker is a subject of ongoing research efforts. Pericentromeric satellite repeats were shown to expand in tumor cells. Here, we hypothesized that the increased release of satellite DNA into the circulation might be a basis for developing a biomarker for the detection of cancer.
Materials and Methods: The study included patients with different cancer types, and controls without cancer. Human satellite 2 repeat (HSATII) from chromosomes 1, 10, or 16 was amplified using extracted DNA from plasma or direct application of diluted plasma in PCR.
Results: We first showed that HSATII DNA levels were higher in patients with cancer than in controls relative to LINE1 element, with chr10-HSATII being the most relevant. Absolute quantification in digital PCR showed much higher levels of chr10-HSATII in patients with breast cancer compared with healthy individuals. Subsequently, employing diluted plasma also revealed that HSATII DNA was present in increased levels in patients with cancer including breast, gastric, lung or bile cancers, sarcoma or Hodgkin's lymphoma than in controls with an AUC of 94% in the ROC curve.
Conclusions: This proof-of-concept study reveals the high potential of HSATII DNA as a surrogate cancer biomarker.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: